Johnson & Johnson $JNJ Stock: RWC Asset Management LLP Increases Stake

RWC Asset Management LLP lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 267,730 shares of the company’s stock after purchasing an additional 5,591 shares during the quarter. Johnson & Johnson makes up about 2.6% of RWC Asset Management LLP’s investment portfolio, making the stock its 7th largest position. RWC Asset Management LLP’s holdings in Johnson & Johnson were worth $70,879,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson during the 2nd quarter worth about $28,000. Matrix Trust Co increased its stake in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after acquiring an additional 54 shares during the period. Montgomery Financial Services LLC bought a new stake in Johnson & Johnson in the second quarter valued at about $43,000. Polaris Financial Partners bought a new stake in Johnson & Johnson in the third quarter valued at about $56,000. Finally, Bullseye Investment Management LLC acquired a new position in Johnson & Johnson in the second quarter worth about $63,000. 69.55% of the stock is currently owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising prostate-cancer data: Experimental drug JNJ-6143 produced tumor-response rates of roughly 69% to 75% in heavily pretreated patients with advanced prostate cancer. The results support further development of the first-in-class RIPTAC drug, although the evidence remains early-stage. What Do Johnson & Johnson Cancer Trial Wins Mean For Its Stock?
• Positive Sentiment: RYBREVANT expansion potential: A subcutaneous RYBREVANT FASPRO combination generated a 77% overall response rate in first-line treatment of advanced head and neck cancer. The findings support the ongoing Phase 3 OrigAMI-5 trial and could broaden the commercial opportunity for a key oncology franchise. RYBREVANT FASPRO Head and Neck Cancer Results
• Positive Sentiment: ERLEADA showed a meaningful benefit: Johnson & Johnson said using ERLEADA before and after surgery reduced the risk of recurrence or death by 62% versus surgery alone in high-risk localized or locally advanced prostate cancer, potentially supporting broader adoption. ERLEADA Surgical Study Results
• Neutral Sentiment: ETF activity showed net selling of JNJ, but this is generally a short-term trading signal rather than a change in the company’s fundamentals.
• Negative Sentiment: An expected orthopedics merger with Smith & Nephew collapsed over leadership disagreements, removing a potential strategic opportunity. The strong cancer data also comes with clinical and regulatory risks because several programs remain in relatively early development.

Johnson & Johnson Stock Up 1.0%

JNJ opened at $266.38 on Tuesday. The firm has a market cap of $641.25 billion, a price-to-earnings ratio of 40.36, a PEG ratio of 2.61 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The firm’s 50-day simple moving average is $265.35 and its 200-day simple moving average is $245.32. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of analyst reports. Johnson Rice cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. UBS Group set a $270.00 price objective on Johnson & Johnson in a research note on Wednesday, October 14th. Citigroup increased their target price on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Guggenheim reissued a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 7th. Finally, Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $275.92.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 64,515 shares of company stock worth $17,271,766. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.